Literature DB >> 31139498

Examining correlations of oxygen sensitive MRI (BOLD/TOLD) with [18F]FMISO PET in rat prostate tumors.

Heling Zhou1, Srinivas Chiguru1, Rami R Hallac1,2, Donghan Yang1, Guiyang Hao1, Peter Peschke3, Ralph P Mason1.   

Abstract

Hypoxia is regarded as a potential prognostic biomarker for tumor aggressiveness, progression, and response to therapy. The radiotracer 18F-fluoromisonidazole ([18F]FMISO) has been used with positron emission tomography (PET) to reveal tumor hypoxia. Meanwhile, blood oxygen level dependent (BOLD) MRI and tissue oxygen level dependent (TOLD) MRI offer insight into oxygenation based on endogenous signals without the need for radiolabels. Here, we compared BOLD and TOLD MRI with [18F]FMISO uptake using Dunning prostate R3327-AT1 tumor bearing rats. BOLD and TOLD MRI were acquired with respect to an oxygen gas breathing challenge. The following day, dynamic PET was performed up to 90 minutes following IV injection of [18F]FMISO. Tumors showed distinct heterogeneity based on each technique. Correlations were observed between magnitude of mean BOLD or TOLD MRI signal responses to oxygen-breathing challenge and initial distribution of [18F]FMISO. Correlations were observed for whole tumor as well on a regional basis with stronger correlations in the well perfused tumor periphery indicating the strong influence of perfused vasculature. After 90 minutes most correlations with signal intensity became quite weak, but correlations were observed between hypoxic fraction based on FMISO and fractions of tumor showing BOLD or TOLD response in a subset of tumors. This emphasizes the importance of considering regional heterogeneity and responsive fractions, as opposed to simple magnitudes of responses. Although the data represent a small cohort of tumors they present direct correlations between oxygen sensitive MRI and PET hypoxia reporter agents in the same tumors, indicating the potential utility of further investigations.

Entities:  

Keywords:  BOLD; MRI; PET; TOLD; Tumor hypoxia; [18F]FMISO; biomarkers; oxygen; prostate tumor

Year:  2019        PMID: 31139498      PMCID: PMC6526364     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  5 in total

Review 1.  Hypoxia Imaging As a Guide for Hypoxia-Modulated and Hypoxia-Activated Therapy.

Authors:  Jeffrey R Brender; Yu Saida; Nallathamby Devasahayam; Murali C Krishna; Shun Kishimoto
Journal:  Antioxid Redox Signal       Date:  2022-01       Impact factor: 8.401

2.  Oxygen-Sensitive MRI: A Predictive Imaging Biomarker for Tumor Radiation Response?

Authors:  Tatsuya J Arai; Donghan M Yang; James W Campbell; Tsuicheng Chiu; Xinyi Cheng; Strahinja Stojadinovic; Peter Peschke; Ralph P Mason
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-03-26       Impact factor: 8.013

Review 3.  Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.

Authors:  Natalie J Serkova; Kristine Glunde; Chad R Haney; Mohammed Farhoud; Alexandra De Lille; Elizabeth F Redente; Dmitri Simberg; David C Westerly; Lynn Griffin; Ralph P Mason
Journal:  Cancer Res       Date:  2020-12-01       Impact factor: 13.312

4.  Convolutional neural networks for head and neck tumor segmentation on 7-channel multiparametric MRI: a leave-one-out analysis.

Authors:  Lars Bielak; Nicole Wiedenmann; Arnie Berlin; Nils Henrik Nicolay; Deepa Darshini Gunashekar; Leonard Hägele; Thomas Lottner; Anca-Ligia Grosu; Michael Bock
Journal:  Radiat Oncol       Date:  2020-07-29       Impact factor: 3.481

Review 5.  Hypoxia and the phenomenon of immune exclusion.

Authors:  Violena Pietrobon; Francesco M Marincola
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.